You are here

BridgeBio

With post hoc analysis, BridgeBio touts case for acoramidis as FDA decision date draws near

Fierce Biotech

Mon, 09/30/24 - 09:57 am

transthyretin amyloid cardiomyopathy

3 FDA approval dates to watch in the year’s final push

Pharma Voice

Wed, 09/11/24 - 11:39 am

Bristol Myers Squibb

ATTR cardiomyopathy

BridgeBio slashes gene therapy budget after early-phase data fall short of 'transformational' target

Fierce Biotech

Wed, 09/11/24 - 11:15 am

clinical trials

BridgeBio contributes rare disease assets to $300M-backed GondolaBio venture

First Word Pharma

Wed, 08/21/24 - 11:22 am

erythropoietic protoporphyria

BridgeBio Stock Makes A Bullish Move On Dwarfism Treatment Results

Investors Business Daily

Tue, 06/4/24 - 11:42 am

BridgeBio taps VCs for $200M, fueling oncology spinout's push to surpass KRAS class

Fierce Biotech

Thu, 05/2/24 - 11:32 am

venture capital

KRAS inhibitors

Bayer pays $310M to buy into BridgeBio heart drug

BioPharma Dive

Mon, 03/4/24 - 11:52 am

transthyretin amyloidosis cardiomyopathy

BridgeBio taps investors for $1.25B to fund showdown with Pfizer

Fierce Biotech

Thu, 01/18/24 - 11:00 am

BridgeBio gears up for FDA review of acoramidis following Phase III results

Clinical Trials Arena

Thu, 01/11/24 - 11:07 am

clinical trials

Pfizer's 'entrenched' tafamidis franchise will be tough to challenge for Alnylam, BridgeBio: analysts

Fierce Pharma

Mon, 09/18/23 - 08:01 pm

clinical trials

BridgeBio Pharma Shares Rise 14% on Expected Results from Heart-Disease Study

Marketwatch

Sun, 07/16/23 - 03:03 pm

transthyretin amyloid cardiomyopathy

Why BridgeBio Pharma Stock Is Plunging Today

Motley Fool

Thu, 06/15/23 - 06:56 pm

clinical trials

Biopharma stocks go back to bleak

EP Vantage

Thu, 04/6/23 - 09:51 am

Apellis Pharmaceuticals

Protagonist Therapeutics

Reata Pharmaceuticals

BioMarin Answers BridgeBio's Challenge with sNDA for Achondroplasia

BioSpace

Wed, 03/8/23 - 09:42 am

BridgeBio Soars 64% And Breaks Out After Smashing Expectations In A Dwarfism Study

Investors Business Daily

Mon, 03/6/23 - 11:09 am

FDA Review: Phanes, Pfizer, GSK and More

BioSpace

Fri, 10/14/22 - 10:38 am

Eagle Pharmaceuticals

Galactin Therapeutics

Gilead Sciences

scPharmaceuticals

$2.4B BridgeBio/Helsinn Liver Cancer Deal Falls Apart

BioSpace

Thu, 10/13/22 - 11:53 pm

BridgeBio's CEO on staying alive, 'motherhood and apple pie'

Fierce Biotech

Thu, 05/26/22 - 10:15 am

When will biotech markets get better? BridgeBio fears they may stay 'pretty bad' until 2024

Fierce Biotech

Tue, 05/24/22 - 10:49 am

BridgeBio adds another $110M to coffers with voucher sale a day after mega BMS deal

Fierce Biotech

Fri, 05/13/22 - 10:50 am

priority review vouchers

Pages